This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Philips' (PHG) New Innovation to Boost Neurovascular Diagnosis
by Zacks Equity Research
Philips (PHG) announces its latest Azurion neuro biplane system, which aims to improve the diagnosis of stroke and major neurovascular diseases. The system is designed for superior patient care.
Patterson Companies (PDCO) Misses on Q3 Earnings, Lowers EPS View
by Zacks Equity Research
Patterson Companies' (PDCO) third-quarter fiscal 2024 results reflect an improvement in Dental Consumable sales, offset by lower Dental Equipment sales. Animal health sales appear weak.
Inogen (INGN) Q4 Earnings Miss Estimates, Gross Margin Improves
by Zacks Equity Research
Inogen's (INGN) fourth-quarter earnings and revenues miss their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.
Masimo (MASI) Q4 Earnings Beat Estimates, Margins Decline
by Zacks Equity Research
Despite strength in the Hearables category, Masimo's (MASI) overall fourth-quarter results reflect soft performances.
OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.
Insulet (PODD) Q4 Earnings, Revenues Top Mark, Margins Expand
by Zacks Equity Research
In the fourth quarter, Insulet (PODD) achieves the milestone of 425,000 estimated active global customers using Omnipod products.
Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down
by Zacks Equity Research
Myriad Genetics (MYGN) registers a strong testing volume improvement across all its businesses in the fourth quarter of 2023.
Alcon (ALC) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Alcon (ALC) delivers impressive performance across its franchises in the fourth quarter of 2023.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.
Quest Diagnostics' (DGX) New Pact to Reduce Food Insecurity
by Zacks Equity Research
Quest Diagnostics' (DGX) recent collaboration aims to advance food access and healthy eating habits for underserved communities.
GE HealthCare (GEHC), Biofourmis Partner to Boost At-Home Care
by Zacks Equity Research
GE HealthCare (GEHC) collaborates with Biofourmis to facilitate the patient's journey throughout the healthcare system and make the transition from hospital to home care easier.
Humana (HUM) Collaborates With Veda to Enhance Efficiency
by Zacks Equity Research
Humana (HUM) partners with Veda to enhance the quality of provider directories.
Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Henry Schein (HSIC) Q4 Earnings Miss, Operating Margin Down
by Zacks Equity Research
Henry Schein (HSIC) posts lower-than-expected earnings and revenues in the fourth quarter of 2023.
Here's Why You Should Buy Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.
Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
Penumbra's (PEN) Q4 revenues register year-over-year growth driven by robust U.S. thrombectomy sales.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Philips' (PHG) New Innovation to Boost Radiation-Free Imaging
by Zacks Equity Research
Philips (PHG) announces its latest LumiGuide imaging technology, which is likely to pave the way for new radiation-free procedures. It will prove beneficial for complex aortic surgeries.
Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEV
HCA Healthcare (HCA) Drives Efficiency With New Outpatient Model
by Zacks Equity Research
HCA Healthcare's (HCA) Sarah Cannon Cancer Institute adopts a new outpatient model for CAR T-cell therapy patients.
Amedisys' (AMED) Q4 Earnings Miss Estimates, Margins Up
by Zacks Equity Research
The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q4 performance.
BD (BDX), Camtech Health Unite to Aid Cervical Cancer Screening
by Zacks Equity Research
BD (BDX) collaborates with Camtech Health to improve the rate of cervical cancer screening in Singapore by offering women an option to self-collect samples in the privacy of their own homes.
Lantheus (LNTH) Q4 Earnings Surpass Estimates, Gross Margin Up
by Zacks Equity Research
Lantheus' (LNTH) robust segmental revenues drive its fourth-quarter performance.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio for Now
by Zacks Equity Research
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.